Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

Status Completed

Clinical Trial Summary

The clinical trial phase 2b is designed to assess the safety and the specific immune response of the active ingredient (protein + adjuvant) in healthy and then in infected school children from 8 to 11 years of age with intestinal and/or urinary schistosomiasis, living in the Valley of the Senegal River, a highly endemic area for schistosomiasis.

Clinical Trial Description

A phase 2b trial, self-contained, open-label, controlled, randomized study in three parallel arms, two of them formed by groups of healthy or infected school children, both receiving three (3) injections at D0, W4 (Week 4), W8; both groups receiving 50 μg Sm14 vaccine candidate solution, combined with 2.5μg GLA-SE. The third group is composed by non-vaccinated infected school children.

Sm14: recombinant protein produced in yeast following Good Manufacturing Practices (GMP) conditions, presented in vials containing 0.55 ml solution Sm14, 0.4 ml solution is diluted with 0.4 ml of GLA (Synthetic Glucopyranosyl lipid A) for intramuscular administration.

Medical examinations are performed at D0 (before injection, 1 hr and 4 hr after), and a safety evaluation at 24 hrs and 48 hrs, after each injection.

Blood analysis: Liver function tests - renal function tests - blood counts, at W-1 before inclusion, and at W9 and W21 during the follow-up.

Blood samples for immune response analysis at D0, W12 and W21. ;

Study Design

Related Conditions & MeSH terms

Schistosomiasis

Clinical Trial Details

NCT number	NCT03799510
Study type	Interventional
Source	Oswaldo Cruz Foundation
Contact
Status	Completed
Phase	Phase 2
Start date	December 13, 2018
Completion date	August 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04115072` - Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study	Phase 2/Phase 3
Not yet recruiting	`NCT05999825` - Sm-p80 Schistosomiasis Challenge Study	Phase 2
Completed	`NCT00463931` - Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana	N/A
Completed	`NCT00276224` - Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia	N/A
Completed	`NCT00215267` - The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda	N/A
Completed	`NCT03845140` - L-PZQ ODT in Schistosoma Infected Children	Phase 3
Completed	`NCT01512277` - Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis	Phase 1
Active, not recruiting	`NCT03910972` - Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults	Phase 1/Phase 2
Completed	`NCT05085470` - Repeated Controlled Human Schistosoma Mansoni Infection	N/A
Completed	`NCT02755324` - Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding	N/A
Recruiting	`NCT05868005` - Delivering a Multi-disease Screening Tool to Migrant Populations	N/A
Active, not recruiting	`NCT01869465` - Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis	N/A
Completed	`NCT01553552` - Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal	N/A
Recruiting	`NCT04589390` - Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension	Phase 2
Completed	`NCT02868385` - Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)	Phase 3
Recruiting	`NCT05762393` - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar	Phase 1
Not yet recruiting	`NCT06182176` - Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control	N/A
Completed	`NCT05292391` - Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults	Phase 1
Completed	`NCT03110757` - A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults	Phase 1
Completed	`NCT01154049` - Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis	Phase 1